FDA's postureShould the FDA become obstacle relevant to Cannabis related treatments, then large segment of US's population (those in need of medical care) will be traveling to places where they could receive such treatments, I reason. In such scenario, it is USA's economically disadvantaged populations that will be discriminated (left out). Being the facilitator of the giant private pharmaceutical industry, the FDA is bluffing in this case I believe. But if it doesn't, it is logical to presume then that in due course both Canada and Mexico will become serious and busy centres for Cannabis related treatments. More things to come..... So yes, not rushing to venture South of the border, is Aphria's well thought out business assessment one supposes.